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Abstract
Background: The aims of this study were to establish 
robust reference intervals and to investigate the factors 
influencing bone turnover markers (BTMs) in healthy pre-
menopausal Spanish women.
Methods: A total of 184 women (35–45 years) from 13 
centers in Catalonia were analyzed. Blood and second void 
urine samples were collected between 8 a.m. and 10 a.m. 
after an overnight fast. Serum procollagen type I amino-
terminal propeptide (PINP) and serum cross-linked C-ter-
minal telopeptide of type I collagen (CTX-I) were measured 
by two automated assays (Roche and IDS), bone alkaline 
phosphatase (bone ALP) by ELISA, osteocalcin (OC) by 
IRMA and urinary NTX-I by ELISA. PTH and 25-hydroxy-
vitamin D (25OHD) levels were measured. All participants 
completed a questionnaire on lifestyle factors.
Results: Reference intervals were: PINP: 22.7–63.1 and 
21.8–65.5 μg/L, bone ALP: 6.0–13.6 μg/L, OC: 8.0–23.0 
μg/L, CTX-I: 137–484 and 109–544 ng/L and NTX-I: 
19.6–68.9 nM/mM. Oral contraceptive pills (OCPs) influ-
enced PINP (p = 0.007), and low body mass index (BMI) 
was associated with higher BTMs except for bone ALP. 
Women under 40 had higher median values of most 
BTMs. CTX-I was influenced by calcium intake (p = 0.010) 
and PTH (p = 0.007). 25OHD levels did not influence BTMs. 
Concordance between the two automated assays for PINP 
and particularly CTX-I was poor.
Conclusions: Robust reference intervals for BTMs in a 
Southern European country are provided. The effects of 
OCPs and BMI on their levels are significant, whilst serum 
25OHD levels did not influence BTMs. Age, calcium intake, 
BMI and PTH influenced CTX-I. The two automated assays 
for measuring PINP and CTX-I are not interchangeable.
Keywords: bone turnover markers; osteoporosis.
Introduction
Biochemical markers of bone turnover (BTMs) are used in 
the clinical setting for the initial assessment of osteoporo-
sis, including the suspicion of secondary causes and the 
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identification of patients with rapid bone loss, but par-
ticularly for monitoring the response to treatment [1–3]. 
For these reasons, it is essential to have robust reference 
ranges of BTMs, and it is very important to have a reliable 
upper limit as well as a low limit value for each marker. 
High BTM levels, particularly those of bone resorption, 
have been linked with a high fracture risk, and if levels are 
increased greatly, causes of high bone turnover other than 
osteoporosis, such as hyperparathyroidism, myeloma or 
thyrotoxicosis, should be ruled out [4, 5]. In addition, it 
has been considered that the goal of oral antiresorptive 
therapy was to reduce BTMs to within the lower half of 
the reference range interval for healthy premenopausal 
women [1]. With the post-marketing use of parenteral and 
more potent anti-resorptive drugs, such as zoledronic acid 
and denosumab [6, 7], the lower limits of BTMs became 
more important than previously, as not only has it been 
questioned if decreases of BTMs below the reference inter-
val could harm microdamage repair of the bone, but they 
also may be helpful in taking decisions in clinical practice, 
such as whether or not to give the next dose of a potent 
antiresorptive drug (e.g. zoledronic acid) [6–8].
At present, in some countries such as in Spain, ref-
erence intervals must be fine-tuned, since they were per-
formed years ago on a low number of individuals [9], or 
were taken from the normalities of commercial brochures. 
In the last few years, reference intervals in premenopau-
sal women from different countries in Europe (UK, France, 
Belgium and Denmark) [10, 11] and the US [11, 12] have 
been reported. In addition, data from Germany on men 
and women have been recently published [13]. In Spain, 
there are data on PINP and CTX-I in older men and in 
postmenopausal women [14–16], as well as on CTX-I in a 
subset of 50 premenopausal women [17]. As our aim was 
to establish reliable BTM intervals, it was tempting to use 
the reference intervals for BTMs in premenopausal women 
from a country with a geographical proximity, such as 
France [11]. However, we could not assume that the envi-
ronmental and lifestyle factors are the same in French and 
in Spanish women. In fact, we were further interested in 
comparing our data with those reported in other European 
countries in order to evaluate if premenopausal women 
from a Southern European setting have different or similar 
bone remodeling activity than those from Western, North-
ern or Central Europe. Therefore, and taking into consid-
eration the importance of the pre-analytical variability 
when establishing the reference intervals, we designed 
this study involving a large cohort of healthy women born 
in Spain, with an age range of between 35 and 45. This 
age range was taken because BTM levels were considered 
to be stable by Glover et  al. in their study assessing the 
reference interval in premenopausal British women [18]. 
In addition, other sources of variability were minimized, 
since the circadian rhythm and the influence of feeding 
are well known contributing factors in the pre-analytical 
variability of BTMs [1]. Furthermore, the seasons of the 
recruitment period, and consequently vitamin D levels 
were taken into account as possible sources of variability, 
even in a sunny country, such as Spain.
The aims of this study were to establish robust refer-
ence intervals for BTMs in healthy premenopausal Spanish 
women and to analyze the factors influencing their levels.
Materials and methods
Subjects
A total of 185 women from 35 to 45 years of age (mean: 40.2±3.1) from 
13 medical centers in Catalonia (Northeast of Spain) were recruited 
as volunteers. Most of them were health workers and their friends. 
The study was carried out between February 10 and June 13, 2013. 
All women were healthy, non-pregnant and were regularly menstru-
ating. All participants completed a questionnaire on medical and 
lifestyle factors, including height and weight, previous pregnancies, 
alcohol consumption, tobacco habit (current smokers), dairy prod-
ucts intake, physical exercise, drugs, including oral contraceptives 
(OCP), and any medical condition. We calculated the body mass 
index (BMI) as the weight (kg) divided by height (m) squared; alco-
hol consumption as standard drink units (ethanol content of 8–10 g) 
per day; dietary calcium intake, by the number of portions of dairy 
products multiplied by the milligrams of calcium per portion per day, 
and physical activity according to four categories: from inactivity to 
high intensity exercise. We excluded women with a recent pregnancy 
or fracture (within 12 months) or with a surgical procedure in the last 
3 months, as well as women with any medical condition interfering 
with bone metabolism. Women on OCP and those with low vitamin D 
serum levels were included in the study. Ethical approval from each 
participating center was obtained as well as written informed con-
sent from each participant in the study.
Biochemical and hormonal tests
Blood and second void urine samples were collected between 8 and 
10 a.m. after an overnight fast in all individuals. Serum and urine 
samples were stored at −20 °C and plasma samples were stored at 
−80  °C until analysis. All the assays were performed by a central 
laboratory.
Serum bone alkaline phosphatase (bone ALP) was measured by 
ELISA (Immunodiagnostic Systems, Boldon, UK), with an analytical 
sensitivity of 0.7 μg/L. Serum cross-linked C-terminal telopeptide of 
type I collagen (CTX-I [Roche]) and total procollagen type I amino-
terminal propeptide (PINP [Roche]) were measured using electro-
chemiluminescence automated immunoassays (Elecsys, Roche 
Diagnostics, Mannheim, Germany). The analytical sensitivities were 
70 ng/L and 5 μg/L, respectively. Serum CTX-I (CTX-I [IDS]) and intact 
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PINP (PINP [IDS]) were also measured using chemiluminescence 
automated immunoassays (IDS-ISYS, Immunodiagnostic Systems). 
The analytical sensitivities were 33 ng/L and 1 μg/L, respectively. Uri-
nary cross-linked N-terminal telopeptide of type I collagen (NTX-I) 
was measured by ELISA (Osteomark® NTX-I, Alere, Scarborough, ME, 
USA), with an analytical sensitivity of 20 nM. NTX-I was expressed 
as a ratio to creatinine. Osteocalcin (OC) was measured by IRMA (Cis 
Bio, Sorgues, France), with an analytical sensitivity of 0.4 μg/L.
Plasma parathyroid hormone (PTH) (Centaur XP, Siemens) and 
serum 25-hydroxyvitamin D (25OHD) (Liaison, Diasorin, Stillwater, 
MN, USA) were measured using automated immunoassays in all 
participants. The analytical sensitivities were 0.3 pmol/L and 9.98 
nmol/L, respectively. Reference ranges were 1.1–6.8 pmol/L for PTH. 
A concentration of 25OHD <50 nmol/L was considered as vitamin D 
deficiency.
Statistical analysis
A quantile regression was used to estimate the 5%, 50% and 95% 
percentiles and their 95%CI for the BMTs and to obtain unadjusted 
and OCP adjusted p-values. Standard non-parametric tests for 
Table 1: Demographic characteristics of all individuals.a 
Age, years   40 (38–43)
BMI, kg/m2   22.2 (20.5–24.8)
Contraceptive pills   20 (10.9)
Previous fractures   3 (1.6)
Current smokers   39 (21.3)
Alcohol use   40 (21.9)
Alcohol intake units   1 (0.5–1)
Physical exercise  
 Sporadic   40 (21.9)
 Regular, low intensity   77 (42.1)
 Regular, high intensity   25 (13.7)
Previous pregnancy   133 (73.5)
Previous nephrolithiasis   16 (8.7)
Calcium intake, mg/d   621.1 (479.1–869.5)
25-hydroxyvitamin D, nmol/L   44.93 (32.4–54.9)
PTH, pmol/L   4.5 (3.4–6.0)
Statistics are n (%) or median (25th–75th percentiles). aIncluding 
oral contraceptive users.
Table 2: Reference values for the bone turnover markers in all individuals and in non-oral contraceptive users. 
   All individuals (n = 184) 
 
 
 Non-oral contraceptive users (n = 164)
Percentile 5
(95% CI)
 
 
Percentile 50 
(95% CI)
 
 
Percentile 95
(95% CI)
Percentile 5
(95% CI)
 
 
Percentile 50
(95% CI)
 
 
Percentile 95
(95% CI)
Bone ALP, μg/L   6.0 (5.4–6.6)  9.3 (8.8–9.8)  13.8 (12.0–15.5)  6.0 (5.3–6.7)  9.4 (8.9–9.9)  13.6 (11.8–15.4)
PINP (Roche), μg/L   20.8 (18.4–23.2)  35.9 (33.8–37.9)  60.6 (52.0–69.1)  22.7 (20.0–25.5)  36.0 (33.8–38.2)  63.1 (51.8–74.4)
PINP (IDS), μg/L   20.8 (18.9–22.7)  35.8 (33.2–38.3)  64.9 (57.1–72.7)  21.8 (19.6–24.0)  36.6 (34.0–39.1)  65.5 (54.0–77.0)
NTX-I, nM/mM   19.3 (15.9–22.7)  32.7 (30.1–35.3)  68.9 (60.1–77.8)  19.6 (15.9–23.3)  32.9 (29.7–36.1)  68.9 (55.8–82.1)
CTX-I (Roche), ng/L  137 (122–152)  250 (230–270)  480 (429–531)  137 (120–154)  255 (234–276)  484 (351–617)
CTX-I (IDS), ng/L   107 (92–123)  246 (219–272)  541 (439–643)  109 (91–127)  249 (222–277)  544 (408–680)
OC, μg/L   8.0 (6.7–9.3)  14.0 (13.4–14.6)  23.0 (20.4–25.6)  8.0 (7.1–8.9)  14.0 (13.3–14.7)  23.0 (19.9–26.1)
continuous variables and the Fisher’s exact test were used to assess 
the influence of factors on BTMs. To compare the two analytic assays 
we used the Bland-Altman method as well as the Lin’s concordance 
coefficient (LCC) and the corresponding 95% CI. The Bland-Altman 
95% limits of agreement (mean bias± 2  SD) procedure, based on 
comparison of the mean of two methods against its difference, uses 
datascale assessment to analyze the accuracy (i.e. bias) and the 
amount of variation or precision between any two measured values 
[19, 20]. The Lin coefficient combines measures of both precision 
and accuracy to determine whether the observed data deviate sig-
nificantly from the line of perfect concordance, which occurs at 45°, 
i.e. it assesses the linear relationship between two variables under 
the constraint where the intercept is zero and the slope is one. The 
value of Lin’s coefficient increases as the accuracy and precision of 
the observed data improve [21–23].
Results
In this study, 185 premenopausal women were recruited, 
and of these women we analyzed data from 184 (one 
subject was excluded because of unreliable outlier values 
in all BTMs). Their demographic characteristics are shown 
in Table 1. Reference intervals for all BTMs (5%, 50% and 
95% percentiles, as well as their 95% CI) obtained from 
the entire group of women and from the 164 women who 
were not on OCP are shown in Table 2. Thus, OCP in 20 
women (10.9%) influenced PINP levels (p = 0.007) with a 
trend on bone ALP levels (p = 0.09).
Age (cut-off point at 40 years), when adjusted by oral 
contraceptive use, was not significant for any of the bone 
marker values (Bone ALP p = 0.273, PINP [Roche] p = 0.272, 
PINP [IDS] p = 0.288, CTX-I-Roche p = 0.306, CTX-I [IDS]
p = 0.318, NTX-I p = 0.253, OC p = 0.215). However, when 
excluding OCP users, there were significant differences or 
trends for all BTM values when women from 35 to 39 and 
40 to 45 were analyzed separately. Thus, all median values 
were higher in women under 40, although the observed 
relative differences were <15% of the normal reference 
intervals.
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Figure 1 (continued)
After excluding OCP users, low BMI was associated 
with higher levels of all BTMs except for bone ALP, when 
comparing women according to their median value of 
BMI. By contrast, neither alcohol consumption, observed 
in 21.9% of subjects in low amounts (1 [0.5–1] units), nor 
current smoking (20.2% of subjects) showed any effect on 
BTM levels. Exercise-influenced bone ALP, but not other 
BTM levels when subjects were classified according to 
those engaged in regular exercise and those who were 
sedentary (8.9 [7.5–10.4] vs. 9.9 [8.2–11.7] μg/L, p = 0.005). 
Dietary calcium intake influenced CTX-I [Roche] and CTX-I 
[IDS] serum levels, as CTX-I [Roche] decreased as the 
calcium intake increased (  ≤  400,  > 400 –   ≤  800 and  > 800 
mg/day): 290 (210–400), 260 (190–320) and 220 (170–280) 
ng/L, respectively, p = 0.010; CTX-I [IDS] levels showed the 
same trend (p = 0.024). The median value of 25OHD was 
44.9 (32.4, 54.9) nmol/L, with levels of 25OHD being higher 
than 50 nmol/L in nearly 40% of subjects. There were no 
differences in any BTM levels when comparing women 
with those above or below the median value or according 
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to 25OHD tertiles (p33: 34.94; p66: 49.92 nmol/L). However, 
PTH showed a statistically significant relationship with 
CTX-I [Roche] when assessed both as a continuous vari-
able (p = 0.007) and when using the median as a cut-off 
point (p = 0.016). By contrast, CTX-I [IDS] was not associ-
ated with PTH levels (p = 0.305 and p = 0.312, respectively). 
Figure 1 shows the influence of different variables accord-
ing to the median and Q1; Q3 values.
The Lin’s concordance (95% CI) between the two 
automated assays used for measuring CTX-I and PINP was 
0.851 (0.812–0.883) for CTX-I and 0.878 (0.841–0.906) for 
PINP. The Bland-Altman bias (95% limits of agreement) 
was −0.011 (−0.153–0.131) and −1.282 (−14.026–11.461) for 
CTX-I and PINP, respectively (Figure 2, Table 3).
Discussion
This study provides robust reference intervals for BTMs 
in Spanish women and contributes to the identification 
Figure 1 (continued)
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Figure 1 (continued)
of reference ranges for BTMs in Southern Europe. In addi-
tion, our results reinforce the effects of OCP and BMI on 
their levels, as OCP use was associated with lower levels 
of most bone formation markers and low BMI-induced 
higher levels of most BTMs. Interestingly, calcium intake 
influences serum CTX-I values.
It is of value to assess whether reference intervals 
for BTMs in premenopausal women differ according to 
the location of the country in Europe. This has been ana-
lyzed by Glover et al., comparing European data from UK, 
France and Belgium [11]. Surprisingly, Spanish values for 
bone ALP, PINP and serum CTX-I were quite similar to UK-
reported values, instead of those of French women from 
our neighboring country. Indeed, PINP and CTX-I, higher 
in France than in UK have been attributed to different life-
style factors and BMI [11]. In addition, we found similar 
PINP and serum CTX-I values to those published by other 
authors in Italian and in German premenopausal women 
aged 35–45 years, particularly for total and intact PINP 
[13, 24]. However, these affirmations must be taken with 
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Figure 1 (continued)
caution as the compared studies were performed not only 
in different populations, but also under different analyti-
cal conditions. Thus, although all of them reported refer-
ence intervals for PINP and serum CTX-I using automated 
assays, samples were analyzed in different batches, and 
some of them in different laboratories. In addition, there 
were some discordant pre-analytical conditions. Most 
studies were performed in premenopausal women but 
the age ranges were not identical, and contrary to Glover 
et al. [18], we have found that women from 35 to 40 have 
slightly higher BTM values ( < 15% in magnitude) than 
those between 40 and 45 years of age. In addition, most, 
but not all samples were collected between 8 a.m. and 
10 a.m. Interestingly, Australian harmonized reference 
intervals for PINP and CTX-I in premenopausal women 
have been recently published, and the intervals are much 
wider. Indeed, the reference intervals for PINP [Roche] are 
15–70 ng/mL in an age range of 25–49 years, with values 
of 15–90 ng/mL in women aged 20–24  years [25]. These 
results suggest that the reference intervals for PINP as well 
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Figure 1:  Factors affecting bone turnover markers.
(A) Bone ALP; (B) PINP [Roche]; (C) OC; (D) CTX-I [Roche] and (E) NTX-I. *p < 0.05. Bone ALP, bone alkaline phosphatase; CTX-I [Roche], serum 
cross-linked C-terminal telopeptide of type I collagen; OC, osteocalcin; PINP [Roche], total procollagen type I amino-terminal propeptide; 
NTX-I, urinary cross-linked N-terminal telopeptide of type I collagen.
as for CTX-I, and probably for other BTMs, may be differ-
ent when assessing a broad age range in the premenopau-
sal population. Our reference intervals, established in a 
narrow age range (35–45 years), may be particularly useful 
in the assessment of response to antiresorptive therapy in 
postmenopausal osteoporosis [26].
The International Osteoporosis Foundation (IOF) and 
the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) recommended PINP and CTX-I 
as the reference BTMs in clinical studies [26, 27]. From our 
perspective, PINP is a very robust bone marker, as among 
all the analyzed factors possibly affecting BTMs, only BMI 
influenced its values after excluding OCP use. By contrast, 
CTX-I was influenced not only by age and BMI, but also by 
the dietary calcium intake and PTH values. This is in con-
trast with the findings of Eastell et al., who found that PTH 
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Figure 2:  Bland-Altman plots of agreement.
(A) PINP; (B) CTX-I. CTX-I [IDS], IDS-ISYS serum cross-linked C-terminal telopeptide of type I collagen; CTX-I [Roche], Elecsys serum cross-
linked C-terminal telopeptide of type I collagen; PINP [IDS], intact procollagen type I amino-terminal propeptide; PINP [Roche], total procol-
lagen type I amino-terminal propeptide.
levels did not affect CTX-I values, and bone ALP was the 
only BTM correlated with PTH [10]. Similar to our results, 
Michelsen et  al. found an association between PTH and 
CTX-I [13].
The relationship between BTMs and 25OHD levels has 
received particular attention in most recent publications. 
We found no difference in BTM levels when classifying 
individuals according to the median values or to tertiles, 
or according to levels higher or <50 nmol/L of 25OHD. Only 
OC showed different values in vitamin D-replete women 
when compared with those with vitamin D insufficiency 
or deficiency (25OHD  < 75 and  < 50 nmol/L, respectively). 
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However, the low number of vitamin-D replete individuals 
(n = 6) makes these differences of doubtful significance. 
Also, some authors have not found significant differences 
in BTMs when premenopausal women were classified in 
vitamin D deficient, insufficient or replete categories [18]. 
Yet other studies found a significant correlation between 
25OHD levels and bone ALP [10, 11, 13]. It may be argued 
that 25OHD levels in our individuals were low, as the 
median value was 44.9 nmol/L, and more than 50% of 
them had 25OHD levels <50 nmol/L. Nonetheless, these 
are the values in healthy young women from our sunny 
country between February and June.
A relevant contribution of this study is the compari-
son of the two major automated assays used in Europe to 
perform PINP and CTX-I measurements. We found that 
there was a poor concordance and a clear trend with a neg-
ative slope for both analytes, and therefore, the interpre-
tation of the bias could not be considered homogeneous 
along the observed values of CTX-I and PINP. The mean 
differences were more different from the null (zero dif-
ferences) for larger values. Although the results were not 
homogeneous, median levels of PINP [Roche] were very 
similar to the median levels of intact PINP (PINP [IDS]) 
(36.0 and 36.6 μg/L, respectively), and we found higher 
median values for Elecsys CTX-I (CTX-I [Roche]) when 
compared with the IDS-ISYS assay (CTX-I [IDS]) (255 and 
249 ng/L, respectively). Also, it has been pointed out that 
the major automated assays for measuring PINP provide 
harmonized results [28]. Although the reference intervals 
are similar, particularly when measuring PINP, our results 
support the fact that the obtained values are not inter-
changeable. As a consequence, the interpretation of PINP 
and CTX-I results and their reference intervals need to be 
established for each assay method, most importantly for 
CTX-I.
The strengths of this study are the homogeneous pre-
analytical and analytical conditions, such as a narrow age 
range of healthy women between 35 and 45 years of age, 
morning fasting samples between 8:00 and 10:00 a.m. 
and a central specialized laboratory, which decrease the 
degree of variability. The limitations of this study are the 
low number of individuals, the absence of bone mineral 
density data and the low values of 25OHD in a large pro-
portion of the series. However, this fact reflects the vitamin 
D status in healthy young women in our country.
In conclusion, this study provides reference intervals 
of BTMs in healthy young women from a sunny Southern 
European country. Interestingly, BTM values are similar 
to those reported in UK, Germany and Italy, but differ-
ent from Belgium and France, our neighbouring country. 
Taken together, it is recommended to establish reference 
intervals in each country, as a geographical neighbour-
hood does not imply exchangeable values for BTMs. 
Furthermore, reference intervals must be based on meas-
urements with the same assay.
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Table 3: Bland and Altman Bias and Lin’s concordance coefficient for the two assays. 
  CTX-I  PINP
Bland-Altman agreementa    
 Bias (95% limits of agreement)b   −11.215 (−153.099–130.668)  −1.282 (−14.025–11.461)
 Intercept (95% CI)c   67.994 (46.273–89.715)  4.513 (1.707–7.319)
 Slope (95% CI)c   −0.286 (−0.357 to −0.215)  −0.154 (−0.224 to −0.083)
Lin’s concordance coefficient (95% CI)   0.851 (0.812–0.883)  0.878 (0.841–0.906)
Pearson lineal correlation coefficient (Ro) (p-value)   0.886  0.891
  (p < 0.001)  (p < 0.001)
CI, confidence intervals; SD, standard deviation. aAverage versus mean difference assessment for the pairwise comparisons; bMean bias; 
cSlope and intercept for the average versus mean difference assessment linear regression.
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